<DOC>
	<DOCNO>NCT00358488</DOCNO>
	<brief_summary>This study design determine efficacy safety new long-acting beta-agonist asthma patient ( GSK159797 ) follow dose 14 day .</brief_summary>
	<brief_title>Study Investigating Repeat Doses Of A New Medication ( GSK159797 ) In Asthmatic Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Subjects document history persistent asthma use corticosteroid total daily dose 200 200mcg FP equivalent corticosteroid Female subject use acceptable birth control method Nonsmokers FEV1 60 90 % predicted Increase FEV1 12 % great 300mL great salbutamol use Exclusion criterion : Past present disease condition Normal screen Holter ECG Respiratory tract infection within 4 week screen History life threaten asthma Previous use COA</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Asthmatic patient</keyword>
	<keyword>GSK159797</keyword>
	<keyword>Efficacy</keyword>
</DOC>